May 3, 2005 by Charly TraversIs Geron a Rule Breaker?At the forefront of stem cell research, can the company live up to its lofty potential?
Apr 29, 2005 by Charly TraversValue in Drug Stocks?Looking at some big pharma companies and liking what you see? Take a peek at biotech, too.
Apr 28, 2005 by Charly TraversQLT's a Clutch PerformerPharma continues to deliver growth through difficult times.
Apr 27, 2005 by Charly TraversThanks for the Ride, TranskaryoticSelling was the right move, but it's hard to let go of stocks you like.
Apr 27, 2005 by Charly TraversVertex's Emerging PipelineEarly-stage drugs, including one for hepatitis C, are moving forward.
Apr 25, 2005 by Charly TraversWhere Is QLT going?Upcoming conference call needs to address the question.
Apr 21, 2005 by Charly TraversSynagis Has Some Legs LeftThe mature drug still generates big numbers for MedImmune.
Apr 19, 2005 by Charly TraversA Rising Star in BiotechIdenix is following a proven path to success: novel drug development.
Apr 12, 2005 by Charly TraversWhere Did the Earnings Go?Expensing stock options will not be kind to some prominent biotechs.
Apr 8, 2005 by Charly TraversThe FDA Hammers PfizerRegulatory agency orders a billion dollar blockbuster off the market.
Apr 5, 2005 by Charly TraversHas Elan Been KO'd?It may have lost its blockbuster drug, but is it down for the count?
Mar 29, 2005 by Charly TraversA Biotech Value PlayTo be a Rule Breaker, you have to invest against the grain.
Mar 22, 2005 by Charly TraversStock Madness 2005: Protein Design Labs vs. TaserOne keeps you healthy; the other keeps you safe. But which one will make your portfolio happier?
Mar 22, 2005 by Charly TraversDo Good Drugs Guarantee Investment Success?By the time you know a drug is good, are you late to the party?
Mar 17, 2005 by Charly TraversStock Madness 2005: Geron vs. UTStarcomBiotech faces off against telecom -- which company gets your vote?
Mar 15, 2005 by Charly TraversPDL Eyeing Up ProfitsA timely acquisition is paying off for this drugmaker.
Mar 15, 2005 by Charly TraversThe Best Company I've Never OwnedWaiting for the perfect time to buy? Don't. You might never get in the game.
Mar 8, 2005 by Charly TraversAfter the Crash, Is Biogen IDEC a Buy?Has the recent stock plunge been an overreaction?
Mar 4, 2005 by Charly TraversThe Sharks Are CirclingMajor stock declines are too often followed by class action suits in the drug industry.
Mar 1, 2005 by Charly TraversFrom Rags to RichesOne biotech's fate reveals the formula for spotting turnaround investments.
